Dani Castillo (@DaniCastilloMD) ranks #15 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 6 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: INCB161734, XmAb819, CLARITY-Gastric01 (CG-01). CMS Open Payments lists $23,927 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 3 trials discussed by name
- GI Cancer: US #15 · 6 physicians engaged
- Leading physician voice: #3 of 10 physicians on INCB161734
- CMS Open Payments lists $23,927 in 2025 general payments.
This Month
What Dani Castillo has posted in the last 30 days. Updated November 10, 2026.
KRAS G12D rapidly becoming one of the most exciting targets in GI oncology. INCB161734,oral selective KRAS G12D inhibitor, advance in PDAC and CRC, bringing the field closer to a targeted option for one of the most common KRAS mutations. #GIOnc #ESMO26 #CRC #KRAS https://t.co/sNvXmJ7p5G
Exciting to see novel immune-engaging strategies in RCC. XmAb819, ENPP3×CD3 bispecific T-cell engager, showed activity in heavily pretreated ccRCC, highlighting potential of ENPP3 as a therapeutic target beyond VEGF, IO, HIF-2α pathways. #ESMO2026 @montypal @cityofhope @OncoAlert https://t.co/YZ5fd0BXhK
As co-author, excited to share CLARITY-Gastric01 data. Sone-Ve showed a meaningful survival benefit for pts with previously treated CLDN18.2-positive GC/GEJ cancers, reinforcing CLDN18.2 as a key therapeutic target beyond the frontline setting. #ESMO2026 #GIOncology https://t.co/P1Y1RqW4i2
Who Amplifies Dani Castillo
Physicians who reposted Dani Castillo’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #15 | — | 6 | 9 | Full ranking |
What Colleagues Are Saying About Dani Castillo
2026 posts by fellow physicians that mention @DaniCastilloMD, quoted word for word.
Eager to meet folks at the @cityofhope booth (Hall 8, #8038) Sunday at 1 pm here at #ESMO26! If you are interested in careers in #oncology, we would love to meet you! Here now with @DaniCastilloMD & @RWinayak! https://t.co/eLDIXiiygT
Trials Dani Castillo Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| INCB161734 | 1 | #3 of 10 | Oct 25, 2026 |
| XmAb819 | 1 | #8 of 15 | Oct 25, 2026 |
| CLARITY-Gastric01 (CG-01) | 1 | #11 of 26 | Oct 25, 2026 |
Dani Castillo on INCB161734
KRAS G12D rapidly becoming one of the most exciting targets in GI oncology. INCB161734,oral selective KRAS G12D inhibitor, advance in PDAC and CRC, bringing the field closer to a targeted option for one of the most common KRAS mutations. #GIOnc #ESMO26 #CRC #KRAS https://t.co/sNvXmJ7p5G
Dani Castillo on XmAb819
Exciting to see novel immune-engaging strategies in RCC. XmAb819, ENPP3×CD3 bispecific T-cell engager, showed activity in heavily pretreated ccRCC, highlighting potential of ENPP3 as a therapeutic target beyond VEGF, IO, HIF-2α pathways. #ESMO2026 @montypal @cityofhope @OncoAlert https://t.co/YZ5fd0BXhK
Dani Castillo on CLARITY-Gastric01 (CG-01)
As co-author, excited to share CLARITY-Gastric01 data. Sone-Ve showed a meaningful survival benefit for pts with previously treated CLDN18.2-positive GC/GEJ cancers, reinforcing CLDN18.2 as a key therapeutic target beyond the frontline setting. #ESMO2026 #GIOncology https://t.co/P1Y1RqW4i2
Dani Castillo’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Very informative session on Concepts in Precision Oncology chaired by Dr. Oh discussions on next-generation ADC strategies, innovative clinical trial designs, and how precision medicine continues to reshape oncology drug development. #ESMO2026 #PrecisionOncology #ADC https://t.co/iUYHqj6Ppg
Chronological age ≠ biological age. Fit geriatric GI cancer pts may still benefit from curative-intent therapy. Immunotherapy responses aren't necessarily diminished by age, and the microbiome may play a role. Patient goals should guide every decision. #GIOn #ESMO2026 https://t.co/WcHGVzQidy
Industry Payments
CMS Open Payments · 2025 general payments
$23,927 across 25 payments